https://charts.traderzeitung.de/phases/US91678A1079
string(1392) "{"isin":"US91678A1079","name":"Upstream Bio Inc","stock_id_xnas":62792676,"stock_id_xnys":null,"generated_at":"2026-08-21 17:24:00","days":[{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.52,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.85,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-8.9096},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.93,"close_at":"2026-08-21 17:19:00","complete":false,"perf_pct":1.1679},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Upstream Bio Aktie News & Nachrichten
Trading-Room

Upstream Bio Aktie News & Nachrichten

[WKN: A40QNK | Symbol: UPB]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Upstream Bio

Upstream Bio Inc.: Piper Sandler bestätigt vor wichtigen Studiendaten die Einschätzung auf "Overweight" mit 326 % Kurspotenzial

Upstream Bio Inc. (UPB) ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf...

  • ‹
  • 1
  • ›
Upstream Bio Nachrichtenticker öffnen
MT Newswires 12.06.2026 13:25 Uhr

JPMorgan stuft Upstream Bio von Overweight auf Neutral herab, senkt Kursziel von 35 $ auf 8 $

07:24 AM EDT, 06/12/2026 (MT Newswires) -- Upstream Bio (UPB) hat eine durchschnittliche Kaufempfehlung und ein mittleres Kursziel von 38,43 $, laut v

MT Newswires 03.06.2026 12:31 Uhr

HC Wainwright nimmt die Coverage für Upstream Bio mit 'Kaufen'-Rating und einem Kursziel von $36 auf

06:30 AM EDT, 06/03/2026 (MT Newswires) -- Upstream Bio (UPB) hat ein durchschnittliches 'Kaufen'-Rating und ein mittleres Kursziel von $45, laut Anal